羟氯喹与狼疮肾炎患者肾小球滤过率下降减缓相关
该回顾性纵向起始队列纳入209例经活检证实的狼疮肾炎患者,以时变协变量分析羟氯喹暴露与 sustained eGFR 下降≥30%和≥40%的关联。结果显示,羟氯喹暴露与eGFR下降≥30%或≥40%的风险分别降低60%和62%相关,慢性肾脏病分期≥3期患者风险降低77%;诊断后前5年和前10年内,羟氯喹暴露使年eGFR斜率下降分别减少5.12和3.17 mL/min/1.73 m²。作者结论认为羟氯喹对狼疮肾炎肾功能有早期和长期获益,应鼓励所有狼疮肾炎患者使用羟氯喹。
要点
- 在209例活检证实的狼疮肾炎患者中,33%和23%分别出现eGFR下降≥30%和≥40%。
- 时变羟氯喹暴露与eGFR下降≥30%或≥40%的风险分别降低60%和62%相关(经倾向评分校正)。
- 慢性肾脏病分期≥3期患者使用羟氯喹与eGFR下降风险降低77%相关。
核心结论
- 羟氯喹使用与狼疮肾炎患者肾功能早期和长期获益相关,包括慢性肾脏病分期≥3期的患者。
- 作者认为应鼓励所有狼疮肾炎患者使用羟氯喹。
研究设计与样本
- 回顾性纵向起始队列研究,纳入经活检证实的狼疮肾炎患者209例。
主要发现
- 209例患者中,33%出现eGFR下降≥30%,23%出现eGFR下降≥40%。
- 经倾向评分校正后,时变羟氯喹暴露与eGFR下降≥30%的风险降低60%相关,与eGFR下降≥40%的风险降低62%相关。
- 慢性肾脏病分期≥3期患者使用羟氯喹与eGFR下降风险降低77%相关。
- 羟氯喹暴露使诊断后前5年内年eGFR斜率下降减少5.12 mL/min/1.73 m²,前10年内减少3.17 mL/min/1.73 m²。
临床怎么用
- 作者结论认为应鼓励所有狼疮肾炎患者使用羟氯喹。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Hydroxychloroquine (HCQ) protects kidney function in lupus nephritis (LN) by preventing flares, yet some cohort studies show no significant benefit in kidney function with HCQ. Clarifying these conflicting findings by showing early and long-term benefits of HCQ on kidney function preservation is critical. Therefore, we analyzed data from our retrospective longitudinal inception LN cohort to examine the time-varying effects of HCQ on kidney function decline in LN. METHODS: We analyzed retrospective data from an incident biopsy-proven LN cohort. Creatinine values at LN diagnosis through the last follow-up were abstracted to find the estimated glomerular filtration rate (eGFR). Using HCQ exposure as a time-dependent covariate, we examined associations between HCQ exposure and sustained eGFR decline ≥30% and ≥40%. We also calculated an annual eGFR slope decline by HCQ exposure using linear mixed-effects analysis. RESULTS: Among 209 patients, 33% and 23% experienced eGFR decline ≥30% and ≥40% over time. Time-varying HCQ exposure was associated with a 60% and 62% lower risk of eGFR decline of ≥30% or ≥40%, after adjusting for propensity scores. A 77% lower risk of eGFR decline was noted in patients with chronic kidney disease (CKD) stage ≥3 with HCQ. HCQ exposure reduced the annual eGFR slope decline by 5.12 and 3.17 mL/min/1.73 m2 within the first 5 and 10 years of diagnosis. CONCLUSION: HCQ use was associated with early and long-term benefits on kidney function in LN, including those with CKD stage ≥3. Universal HCQ use should be encouraged in LN patients.
引用
- Garg S, Rovin B, Astor BC, et al. Hydroxychloroquine Associated With Lower Glomerular Filtration Rate Decline in Lupus Nephritis. Arthritis Care Res (Hoboken). 2025. PMID: 40685684. doi:10.1002/acr.25616
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。